High prevalence of iron deficiency among daratumumab‐treated newly diagnosed multiple myeloma patients
British Journal of Haematology · 2026
DOI: 10.1111/bjh.70697 ↗Kurz gefasst
Fachartikel in der Zeitschrift British Journal of Haematology, 2026. Verfasst von Y Lisa Hwa und 21 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology, Mayo Clinic, Rochester, Minnesota, USA. Hauptthemen laut MEDLINE: Multiple Myeloma, Antibodies, Monoclonal, Iron Deficiencies, Anemia, Iron-Deficiency. Die Arbeit nennt 12 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Iron deficiency (ID) is often overlooked in patients with haematological malignancies due to other potential aetiologies. Daratumumab, an anti‐cluster of differentiation 38 (anti‐CD38) monoclonal antibody, is commonly used for treating multiple myeloma (MM) in the upfront and relapsed/refractory settings. Although anaemia is a common haematological toxicity associated with daratumumab, the contribution of ID in MM patients has not been systematically investigated. We conducted a retrospective case–control study to evaluate the prevalence of ID in newly diagnosed MM (NDMM) patients. Cases were patients receiving daratumumab, ixazomib, lenalidomide and dexamethasone (Dara‐IRD, n = 55). We compared this group with an age‐ and sex‐matched cohort of patients with NDMM who received bortezomib, lenalidomide and dexamethasone (VRD, n = 20) as induction therapy. At 1‐year, nearly 50% of Dara‐IRD‐treated patients met the criteria for ID (ferritin
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Hematology, Mayo Clinic, Rochester, Minnesota, USA.
- Department of Oncology, McMaster University, Hamilton, Ontario, Canada.
ORCID-Profile: Y Lisa Hwa, Morie A Gertz, Ronald S Go, Nelson Leung, Joselle M Cook, Moritz Binder, S Vincent Rajkumar, Eli Muchtar
Zitieren
APA
Hwa, Y. L., Jevremovic, D., Pak, K., Kapoor, P., Visram, A., Gertz, M. A., Dingli, D. D., Buadi, F. K., Go, R. S., Warsame, R., Leung, N., Gonsalves, W. I., Hobbs, M. A., Fonder, A. L., Cook, J. M., Binder, M., Hayman, S. R., Kourelis, T., Rajkumar, S. V., …, & Muchtar, E. (2026). High prevalence of iron deficiency among daratumumab‐treated newly diagnosed multiple myeloma patients. British Journal of Haematology. https://doi.org/10.1111/bjh.70697
Vancouver
Hwa YL, Jevremovic D, Pak K, Kapoor P, Visram A, Gertz MA, et al. High prevalence of iron deficiency among daratumumab‐treated newly diagnosed multiple myeloma patients. British Journal of Haematology. 2026. doi:10.1111/bjh.70697
BibTeX
@article{Hwa2026,
author = {Hwa, Y Lisa and Jevremovic, Dragan and Pak, Karen and Kapoor, Prashant and Visram, Alissa and Gertz, Morie A and Dingli, David D and Buadi, Francis K and Go, Ronald S and Warsame, Rahma and Leung, Nelson and Gonsalves, Wilson I and Hobbs, Miriam A and Fonder, Amie L and Cook, Joselle M and Binder, Moritz and Hayman, Suzanne R and Kourelis, Taxiarchis and Rajkumar, S Vincent and Dispenzieri, Angela and Kumar, Shaji K and Muchtar, Eli},
title = {High prevalence of iron deficiency among daratumumab‐treated newly diagnosed multiple myeloma patients},
journal = {British Journal of Haematology},
year = {2026},
doi = {10.1111/bjh.70697}
}
EUVIMED